1 / 8

Keratometric Changes in Noninflammatory Corneal Ectasic Diseases After Intraocular Pressure Reduction

Keratometric Changes in Noninflammatory Corneal Ectasic Diseases After Intraocular Pressure Reduction. Authors has no financial interest. Renata T Kashiwabuchi, Camila Gadelha, Wilson de Freitas, Carlos Arce, Mauro Campos

tayten
Download Presentation

Keratometric Changes in Noninflammatory Corneal Ectasic Diseases After Intraocular Pressure Reduction

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Keratometric Changes in Noninflammatory Corneal Ectasic Diseases After Intraocular Pressure Reduction Authors has no financial interest. Renata T Kashiwabuchi, Camila Gadelha, Wilson de Freitas, Carlos Arce, Mauro Campos Federal University of Sao Paulo, Paulista School of Medicine – Sao Paulo, Brasil

  2. Purpose: To assess possible keratometric changes after intra-ocular pressure reduction and describe any change observed.

  3. Methods • Ten patients: 9 bilateral keratoconus and 1 corneal ectasia after refractive procedure. • All patients were submitted to the follow exams before and after intra-ocular pressure reduction: • Corneal Analysis System EyeSy (EyeSys Laboratories Incorporation, Houston, Texas, USA), • Pentacam (Oculus, Wetzlar, Germany), • Corneo-Gage Plus (Sonogage, Cleveland, OH), • Galilei (Zymer, SMT Swiss Microtechnology AG, Port, Switzerland) • Ocular Respose Analyser (ORA; Reichert Ophthalmic Instruments, Depew, NY), • Intra-ocular pressure was measured by Goldman applanation tonometer in 90 and 180 axes by examiner 1 as well as all exams.

  4. Methods • For each patient one eye was assigned randomly to receive hypotensive drugs. Instructions about the drops were given to the patients by examiner 2. • Examiner 1 has no access to details of random process.

  5. Results (table) • Significant differences were observed in the follow data (hypotensive group): • PIO (Goldman) = 5.45 ± 2.3 mmHg (p=0.00), • Pentacan • Anterior Chamber Depth= 3.5 ± 0.3 µm (p = 0.04) • Anterior Chamber Volume= 218 ± 42.95 mm3 (p= 0.004), • ORA data: • IOPcc= 8.1 ± 3.1 mmHg (p= 0.00), • IOPg= 4.75 ± 2.1mmHg (p= 0.00) • CRF= 6.0 ± 0.4 (p= 0.01).

  6. Results (abbreviation) • IOP (Goldman)= Intra ocular pressure assessed by Goldman Tonometry • Km =mean simulated K power • P= Pentacan • Km post = posterior corneal power • ACV = Anterior Chamber Volume • ACD = Anterior Chamber Depth • G = Galilei • IOPcc = Corneal Compensated Intra Ocular Pressure • IOPg = Goldman Compensated Intra Ocular Pressure • CRF = Corneal Resistance Factor • CH = Corneal Histeresis

  7. Data from hypotensive group

  8. Conclusion: Even though a significant intra-ocular pressure reduction no keratometry changes were observed in no device used.

More Related